Surgery and endoscopy

What it is

Operations such as gastric bypass, sleeve gastrectomy, and related procedures, plus endoscopic options such as endoscopic sleeve gastroplasty and balloons. Procedure types stay details inside those two conversations. This page does not rank operations for you.

What taking part usually involves

Surgery is an operation followed by long-term follow-up: nutrition monitoring, attention to gastrointestinal symptoms, and changes in medicines. Endoscopic procedures are done through the mouth with a scope rather than as conventional surgery, then also need follow-up. Serious adverse events were higher with procedures than with medicines in the comparison used here. The most malabsorptive operations carried the highest long-term harm signal in that package. Guideline referral ranges describe where procedures are discussed. They are not a personal prescription.

What it is commonly confused with

“Endoscopy is just gentler surgery.” “If a shot matches some surgery at one year, surgery is obsolete.” “Observational survival after surgery is the same as a randomized heart-outcome trial.” “If a U.S. algorithm left surgery out, this page shouldn't exist.”

What the evidence shows

A network of 139 trials compared medicines, endoscopic procedures, and surgery. Most surgeries and tirzepatide produced more than 10% total body-weight loss at 26 to 52 weeks. Surgery looked stronger for long-term weight, especially bypass, sleeve, SADI, and BPD.

Endoscopic procedures, except endoscopic sleeve gastroplasty, were less effective than newer obesity medicines. That is why endoscopy stays a different option on this page, not a footnote under surgery. Long-term data were lacking for most medicines and for all endoscopic procedures in this package.

Semaglutide and tirzepatide showed no inferior short-term weight results versus some surgery. That comparison belongs on both this page and the medicines page. It does not merge them. Missing long-term medicine and endoscopy data is the other half of that finding.

Serious adverse events were higher with endoscopic procedures and surgery than with medicines. BPD had the highest long-term harm signal. Highest-effect surgery is not therefore the first conversation.

A large Swedish observational follow-up found lower long-term mortality after surgery versus matched controls (adjusted hazard ratio about 0.71 at 10.9 years, with a later life-expectancy companion). That is important observational evidence. It is not a randomized heart-outcome trial like SELECT.

Who was studied, expectations, and limits

Population and context studied: adults in randomized comparisons of surgery, endoscopic procedures, and obesity medicines, plus long-term observational surgical follow-up. One major U.S. algorithm leaves surgery out of its scope. UK guidance still places procedures in obesity care.

That is the research setting, not a referral decision.

Realistic expectation: surgery can produce larger long-term weight loss than the other procedures studied, with higher serious-event costs than medicines. Endoscopy is a different, generally weaker option except for endoscopic sleeve gastroplasty, and it lacks long-term data here. Limits: short-term similarity between some medicines and some operations is not long-term equivalence; observational survival is not a randomized heart-outcome trial; not a procedure-by-procedure shopping list; not the type 2 diabetes surgery page.